Amanda Garofalo

Vice President, Clinical Operations

As Vice President, Clinical Operations, Amanda Garofalo, MSHS, plays an integral role in delivering our life-changing medicines to patients by strategically enabling the company’s capabilities as a Clinical stage biotech to support the goals of our portfolio of programs as they are developed for the market. Prior to joining Parabilis Medicines, Amanda was the Head of Oncology Delivery and Patient Centricity at EMD Serono (the healthcare business of Merck KGaA in the United States) where she led a global operations team responsible for the operational execution of early to post marketing stage Oncology asset development, including Tepmetko® and Bavencio®. Prior to joining EMD Serono, Amanda played an instrumental role in architecting a successful and flexible Clinical Operations team for Arcus Biosciences.

Amanda has held numerous operational and scientific roles for GlaxoSmithKline, MedImmune, EMD Serono, Arcus Biosciences, and Indivior. During her career, Amanda has focused on clinical trial strategy and execution for a variety of Oncology, Addiction Medicine and Supportive Care treatments, including Tykerb®, Vortrient®, Kesimpta®, Sublocade®, Mekinist®, Tafinlar®, Imfinzi®, Imjudo®, Revolade®, and Tepmetko®. Amanda completed her B.S. in Biology at The College of William and Mary, her M.S. in Health Science at The George Washington University, and an Advanced Management Program at The Wharton School.